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Abstract
Background: CD4+ T cells are of great importance in the pathogenesis of systemic lupus erythematosus (SLE), as
an imbalance between CD4+ regulatory T cells (Tregs) and CD4+ responder T cells (Tresps) causes flares of active
disease in SLE patients. In this study, we aimed to find the role of aberrant Treg/Tresp cell differentiation for
maintaining Treg/Tresp cell balance and Treg functionality.
Methods: To determine differences in the differentiation of Tregs/Tresps we calculated the percentages of
CD45RA+CD31+ recent thymic emigrant (RTE) Tregs/Tresps and CD45RA+CD31− mature naive (MN) Tregs/Tresps, as
well as CD45RA−CD31+ and CD45RA−CD31− memory Tregs/Tresps (CD31+ and CD31− memory Tregs/Tresps) within
the total Treg/Tresp pool of 78 SLE remission patients compared with 94 healthy controls of different ages. The
proliferation capacity of each Treg/Tresp subset was determined by staining the cells with anti-Ki67 monoclonal
antibodies. Differences in the autologous or allogeneic Treg function between SLE remission patients and healthy
controls were determined using suppression assays.
Results: With age, we found an increased differentiation of RTE Tregs via CD31+ memory Tregs and of RTE Tresps
via MN Tresps into CD31− memory Tregs/Tresp in healthy volunteers. This opposite differentiation of RTE Tregs and
Tresps was associated with an age-dependent increase in the suppressive activity of both naive and memory Tregs.
SLE patients showed similar age-dependent Treg cell differentiation. However, in these patients RTE Tresps differentiated
increasingly via CD31+ memory Tresps, whereby CD31− memory Tresps arose that were much more difficult to inhibit
for Tregs than those that emerged through differentiation via MN Tresps. Consequently, the increase in the suppressive
activity of Tregs with age could not be maintained in SLE patients. Testing the Tregs of healthy volunteers and SLE
patients with autologous and nonautologous Tresps revealed that the significantly decreased Treg function in SLE
patients was not exclusively attributed to an age-dependent diminished sensitivity of the Tresps for Treg suppression.
The immunosuppressive therapy reduced the accelerated age-dependent Tresp cell proliferation to normal levels, but
simultaneously inhibited Treg cell proliferation below normal levels.
(Continued on next page)
* Correspondence: andrea.steinborn-kroehl@med.uni-heidelberg.de
2Department of Obstetrics and Gynaecology, University of Heidelberg,
Research Cooperation Unit Gynaecology/Nephrology, INF 162, 69120
Heidelberg, Germany
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Schaier et al. Arthritis Research & Therapy          (2018) 20:278 
https://doi.org/10.1186/s13075-018-1778-6
(Continued from previous page)
Conclusions: Our data reveal that the currently used immunosuppressive therapy has a favorable effect on the
differentiation and proliferation of Tresps but has a rather unfavorable effect on the proliferation of Tregs. Newer
substances with more specific effects on the immune system would be desirable.
Keywords: Systemic lupus erythematosus, T-helper cell differentiation, Regulatory T cells, Proliferation capacity,
Immunosuppressive therapy
Background
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease with multiple clinical manifestations. It is
characterized by periods of active disease and remission.
The pathophysiology of SLE includes strong hyperactivity
of B and T cells, resulting in exaggerated inflammation
and the production of primarily nonorgan-specific auto-
antibodies towards antigens in the nucleus, in the cyto-
plasm, and on the cell surface [1]. Consequently, strong
deposition of immune complexes and complement activa-
tion in blood vessels leads to progressive damage in differ-
ent tissues, with lupus nephritis being the most common
cause of morbidity and mortality [2]. The precise immune
pathogenesis of SLE remains elusive. The production of
autoantibodies by B cells and isotype switching depends
on the help of autoreactive CD4+ T cells and on many
other types of immune cells, such as dendritic cells, mac-
rophages, and neutrophils [3]. Nevertheless, CD4+ T cells
seem to be of greatest importance, as both SLE patients
and lupus-prone mice show a characteristic activation of
these cells, and inhibitors normalizing CD4+ T-cell reac-
tions exhibit therapeutic effects.
Meanwhile, it is known that a fine balance between ef-
fector CD4+ T cells and immunosuppressive regulatory
CD4+ T cells (Tregs) affects the immune homeostasis con-
siderably, whereby the levels and functions of these cells
were shown to be disturbed in autoimmune diseases [4].
Specifically, the interleukin (IL)-17, IL-21 and IL-22 pro-
ducing T-helper (Th)17 cells, a lineage of effector CD4+ T
cells, were found to contribute decisively to exaggerated
inflammation and autoimmunity [5, 6]. A lot of data ob-
tained in MLR/lpr and NZB/NZW mice suggest a key role
of these cells in the pathogenesis of SLE; however, the
therapeutic effects of Th17 cell antagonism for the treat-
ment of SLE were found to be ineffective [7]. Since the ex-
pansion of Th17 cells has always been closely linked to
the simultaneous exhaustion and dysfunction of Tregs,
the development of therapeutics that regulate the imbal-
ance between Th17 cells and Tregs was considered to be
more promising than those that exclusively regulate Th17
cells [8]. A decisive effect of Tregs was shown to maintain
self-tolerance by suppressing autoreactive T cells [9].
Therefore, the number and function of Tregs has been ex-
tensively studied in SLE patients, but the data available are
very contradictory [10, 11]. These discrepancies can result
from the use of different markers to characterize Tregs,
whereby the combination of markers such as FoxP3 or
CD25 with CD127 seems most suitable for characterizing
Tregs in humans [12]. Moreover, the total Treg pool
consists of different Treg subsets, which might differ func-
tionally and could therefore contribute to the pathogenesis
of SLE to varying degrees [13].
Furthermore, the differentiation of both Tregs and re-
sponder T cells (Tresps) or presumably of distinct subsets
of Tregs and Tresps may be disturbed in SLE patients. Re-
cent studies by our group have shown that special physio-
logic or pathologic conditions, such as old age, pregnancy,
or even renal insufficiency in dialysis patients, may affect
the distribution of CD45RA+CD31+ recent thymic emi-
grants (RTEs) from the thymus. Consequently, the already
distributed RTE Tregs/Tresps differentiated more strongly
into CD45RA−CD31− memory Tregs/Tresps (CD31−
memory Tregs/Tresps). Thereby, the differentiation path-
way via CD45RA+CD31− mature naive (MN) Tregs/Tresps
or CD45RA−CD31+ memory Tregs/Tresps (CD31+ mem-
ory Tregs/Tresps) influenced the strength of the suppres-
sive activity of the Tregs on the proliferation of autologous
Tresps considerably. We showed that differentiation via
CD31+ memory Tregs increased the suppressive activity of
the Tregs with age and particularly during pregnancy, while
differentiation via MN Tregs caused decreased Treg func-
tion and loss of tolerance accompanied by the occurrence
of pregnancy complications, such as preeclampsia and pre-
term labor [14–16]. In contrast, we found that the in-
creased differentiation of RTE Tresps via MN Tresps into
CD31− memory Tresps with age in healthy individuals had
been altered to an increased differentiation via CD31+
memory Tresps in old-aged dialysis patients, causing a de-
creased Treg functionality due to strengthened Tresp re-
activity and chronic inflammation in these patients [17].
Such mismatched differentiation may cause the accu-
mulation of senescent Tregs, thereby affecting the re-
activity of the T-cell system substantially. Previous
investigations already indicate that the immune sys-
tem of patients with autoimmune diseases also show
signs of accelerated aging [18].
For SLE patients, age-related changes in the immune
system remain poorly understood. Therefore, we investi-
gated whether increasing age had an effect on the prolifer-
ation, differentiation, and function of both Tregs and
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Tresps in healthy volunteers and SLE remission patients.
With age, we found an increased differentiation of RTE
Tregs via CD31+ memory Tregs and of RTE Tresps via
MN Tresps into CD31− memory Tregs/Tresp in healthy
volunteers. This opposite differentiation of RTE Tregs and
Tresps was associated with an age-dependent increase in
the suppressive activity of both naive and memory Tregs.
In contrast, SLE patients revealed an increased differenti-
ation of the RTE Tresps via CD31+ memory Tresps
instead of MN Tresps into CD31− memory Tresps. Con-
sequently, the increase in the suppressive activity with age
could not be maintained in SLE patients. However, testing
the Tregs of both healthy volunteers and SLE patients
with both autologous and nonautologous Tresps revealed
that the decreased Treg function was not exclusively at-
tributed to an age-dependent diminished sensitivity of the
Tresps for Treg suppression. The dual effect of the im-
munosuppressive medication on both Treg and Tresp cell
proliferation also seemed to impair the autologous Treg
functionality.
Methods
Patient collectives and healthy controls
Peripheral blood samples were collected from 94
healthy controls (mean age 45 ± 18 years, Group 1) and
78 SLE patients (mean age 45 ± 15 years, Group 2). All
SLE patients fulfilled the 1983 revised and 1997 up-
dated criteria of the American College of Rheumatology
(ACR) for SLE [19, 20]. All SLE patients were diag-
nosed to be in remission (Systemic Lupus Erythemato-
sus Disease Activity Index (SLEDAI) ≤ 4), where 56
patients (72%) had a documented period of renal mani-
festation within their disease history. Blood samples
were collected during routine visits to the Department
of Nephrology, University of Heidelberg.
Fluorescence-activated cell sorting (FACS) staining
Peripheral venous blood samples (9ml) were collected from
all participants into EDTA-containing tubes. Whole periph-
eral blood mononuclear cells (PBMCs) were separated using
Ficoll-Hypaque (inno-train Diagnostik GmbH, Kronberg,
Germany) density gradient centrifugation, and subsequently
analyzed with a six-color flow cytometer. Briefly, 8 × 106
PBMCs were surface stained with 10 μl peridinin chlorophyll
(PerCP)-conjugated anti-CD4 (BD Biosciences, Heidelberg,
Germany), 5 μl phycoerythrin-cyanine 7 (PE-Cy7)-conjugated
anti-CD127 (eBioscience, Frankfurt, Germany), 5 μl
allophycocyanin-hilite 7 (APC-H7)-conjugated anti-CD45RA
(BD Biosciences), and 5 μl Alexa-flour 647-conjugated
anti-CD31 (BD Biosciences) mouse monoclonal antibodies.
Intracellular staining for the detection of FoxP3 was per-
formed using a fluorescein isothiocyanate (FITC)-conjugated
anti-human FoxP3 staining set (clone PCH101, eBioscience)
according to the manufacturer’s instructions. Detection of
Ki67-positive cells within total CD4+ T cells, total
Tregs/Tresps, and the different Treg/Tresp subsets was
performed by incubating the fixed cells with 10 μl
PE-conjugated anti-Ki67 monoclonal antibodies (clone
B56, BD Biosciences). Negative control samples were
incubated with isotype-matched antibodies. Forward-
and side-scatter characteristics (FSC and SSC) were
used to identify and exclude dead cells. Cells were ana-
lyzed by a FACS Canto flow cytometer (BD Biosci-
ences). Statistical analysis was based on at least 100,000
CD4+ T cells.
Positive selection of CD4+CD127low+/–CD25+ Tregs
To examine the suppressive activity of CD45RA+ naive
Tregs and CD45RA− memory Tregs, blood samples (50
ml) from 40 healthy controls and 37 SLE patients were col-
lected in EDTA-containing tubes. Ficoll-Hypaque (inno--
train Diagnostik GmbH) density gradient centrifugation
was used to separate the PBMCs. The “Regulatory-T-cell
Isolation Kit II” (Miltenyi Biotec, Bergisch Gladbach,
Germany) was used to purify CD4+CD127low+/–CD25+
Tregs according to the manufacturer’s instructions.
First, CD4+CD127low+/− T cells were isolated by mag-
netic depletion of non-CD4+CD127high+ T cells. In the
second step, the CD4+CD127low+/–CD25+ Tregs were
isolated by positive selection over two consecutive col-
umns. The CD4+CD127low+/–CD25− T cells were ob-
tained in the flow-through fraction and used as Tresps.
The CD4+CD127low+/–CD25+ Tregs were subsequently
retrieved from the columns.
Sorting and functional testing of the different Treg
subsets
For the sorting of the isolated CD4+CD127low+/–CD25+
Tregs into CD45RA+ naive Tregs and CD45RA− mem-
ory Tregs, cells were stained with 5 μl PE-conjugated
anti-CD45RA (BD Biosciences) and 5 μl APC-conjugated
anti-CD45RO (eBioscience) mouse monoclonal anti-
bodies. In all experiments, dead cells were excluded by
FSC and SSC, while the remaining cells were sorted
using a FACS Aria II or FACS Aria III cell sorter (BD
Biosciences).
To analyze the suppressive activity of the isolated
naive CD45RA+ Treg and CD45RA− memory Treg
populations, 2 × 104 Tresps were cocultured with the
purified Treg subsets at ratios of 1:2 to 1:1024 in
96-well v-bottom plates. Depending on the number of
separated cells, the suppression assays were per-
formed as single or multiple determinations. Suppres-
sion assays were performed in a final volume of
100 μl/well of X-VIVO15 medium (Lonza, Verviers,
Belgium). For T-cell stimulation, the medium was
supplemented with 1 μg/ml anti-CD3 and 2 μg/ml
anti-CD28 antibodies (eBioscience, Frankfurt, Germany).
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As controls, CD4+CD127low+/–CD25+ Tregs and Tresps
alone were cultured both with and without any stimulus.
Cells were incubated at 37 °C in 5% CO2. After 4 days,
1 μCi 3H-thymidine (Hartmann Analytic, Braunschweig,
Germany) was added to the cultures and cells were further
incubated for 16 h. The cells were then harvested and 3H
incorporation was measured by scintillation counting. To
compare the suppressive activity of the different Treg sub-
sets in healthy controls and SLE patients, the maximum
suppressive activity (ratio of Tregs to Tresps 1:2) and the
minimum ratio of Tregs to Tresps at which a suppression
of at least 15% could be achieved were calculated [21].
For further examination of Treg and Tresp functional-
ity, blood samples of 14 SLE patients and age-matched
healthy controls were taken and processed as described
above. The obtained naive CD45RA+ Tregs, CD45RA−
memory Tregs, and CD4+CD127low+/–CD25− Tresps were
arranged into a suppression assay in the same way as before,
but both Treg populations from SLE patients were cocul-
tured with Tresps from healthy controls and vice versa.
Statistical analysis
Linear regression was used to evaluate the influence of age
on the composition of total CD4+ T-helper cells with Tregs
and Tresps for both healthy controls and SLE patients
using separate models. The same approach was used for
evaluating the changes with age in the composition of total
Tregs/Tresps with their subsets (RTE, MN, CD31+mem-
ory, and CD31− memory Tregs/Tresps) and for evaluating
changes in the percentage of Ki67+ cells within total Tregs/
Tresps and their subsets (RTE, MN, CD31+ memory, and
CD31− memory-Tregs/Tresps). In addition, we calculated
the Pearson correlation coefficients (r) between age and
the change in the variables. An analogous procedure was
chosen for evaluating the changes in the percentages of
RTE Tregs/Tresp and MN Tregs/Tresps within total naive
CD45RA+ Tregs/Tresps with age or with their Ki67 ex-
pression. Differences between the two patient groups
(healthy volunteers and SLE patients) concerning the above
listed Treg/Tresp subsets were examined using multiple
regression analysis adjusted for the age variable (centered
on the mean), wherein an interaction term of the age and
the patient group was included. Changes of the suppressive
activity of the different Treg subsets (naive CD45RA+
Tregs, CD45RA− memory Tregs) with age were also ana-
lyzed using linear regression. A p value < 0.05 was consid-
ered significant. For all tests, the software package BiAS for
Windows (version 10.06) was used.
Results
SLE remission patients show reduced Treg proliferation
but excessive Tresp proliferation
To examine whether there were age-dependent differ-
ences in the composition of the total CD4+ T-helper
cell pool with total CD4+CD127low+/–FoxP3+ regulatory
T cells (Tregs) and CD4+CD127+FoxP3− responder T
cells (Tresps), we estimated the percentages of both
T-cell subsets in 78 SLE patients and 94 healthy con-
trols of various ages. Furthermore, we determined the
age-dependent proliferation capacity of Tregs and
Tresps by measuring their percentages of Ki67+ cells
and investigated whether there were differences in the
differentiation of Tregs and Tresps between both study
groups. For this, we calculated the percentages of RTE
and MN Tregs/Tresps, as well as CD31+ and CD31−
memory Treg/Tresps within the total Treg/Tresp pool
and determined the proliferation capacity of each Treg/
Tresp subset. To identify differences in the age-
dependent differentiation pathway of RTE Tregs/Tresps
via MN Tregs/Tresps or CD31+ memory Tregs/Tresp
into CD31− memory Tregs/Tresps between healthy
controls and SLE patients, we determined the percent-
ages of RTE and MN Tregs/Tresps within the naive
CD45RA+ Treg/Tresp pool with age and correlated
these data with their proliferation capacity. To investi-
gate the differentiation of resting naive MN Tregs/
Tresps, we correlated their percentage within total
CD31− Tregs/Tresps with their Ki67 expression. Fig-
ure 1 shows the gating strategy that was used in all ex-
periments and Table 1 presents the clinical data of all
participants in this study.
We found that the percentage of CD4+ T-helper cells
was significantly decreased in SLE patients, regardless
of age. However, the proliferation capacity of CD4+
T-helper cells, which increased significantly with age in
healthy controls, was significantly increased in SLE pa-
tients (Fig. 2a). In addition, the percentage of Tregs
within the total CD4+ T-helper pool was strongly in-
creased in these patients (Fig. 2b), while the Tresp pool
was complementarily diminished (Fig. 2c). By measur-
ing the percentage of Ki67+ cells, we noticed an
age-dependent significant increase for both Tregs and
Tresps in healthy volunteers which could not be de-
tected in SLE patients (Fig. 2b, c). Compared with
healthy volunteers, we found an age-independent sig-
nificantly lower percentage of Ki67+ cells in Tregs
(Fig. 2b), but a higher percentage of Ki67+ cells in
Tresps (Fig. 2c) in SLE patients. Presumably, this means
that there is an excessive Tresp cell proliferation in SLE
patients which cannot be sufficiently suppressed by the
immunosuppressive therapy.
SLE remission patients show an increased differentiation
of their Treg pool, but not of their Tresp pool
To detect differences in the differentiation of Tregs/
Tresps between healthy volunteers and SLE patients,
we estimated the percentages of RTE and MN Tregs/
Tresps, as well as CD31+ memory and CD31−
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memory-Tregs/Tresps within the total Treg/Tresp pool
with age in both study groups. During a healthy course of
life, the percentages of RTE and MN Tregs decreased sig-
nificantly, CD31+ memory Tregs did not change, and
CD31− memory Tregs increased significantly within total
Tregs (Fig. 3a). A similar differentiation was revealed for
Tresps, with the exception of MN Tresps which increased
significantly with age (Fig. 3b). It became apparent that
the age-dependent differentiation of Tregs and Tresps was
not principally different between healthy controls and SLE
patients. However, regardless of age, the percentages of
RTE Tregs were significantly decreased, while the
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Fig. 1 Gating strategy for six-color flow cytometric detection of recent thymic emigrant (RTE), mature naive (MN), CD31+, and CD31− memory
regulatory T cells (Tregs)/responder T cells (Tresps). At first, CD4+ T cells (P1) were gated by side scatter characteristics (SSC) versus fluorescence
intensity of CD4 (a). Then CD4+CD127low+/–FoxP3+ Tregs (P2) and CD4+CD127+FoxP3− Tresps (P3) were gated by fluorescence intensity of FoxP3
versus CD127 (b). Ki67+ cells of CD4+CD127low+/–FoxP3+ Tregs (P4) and CD4+CD127+FoxP3− Tresps (P5) were gated by fluorescence activity of
Ki67 versus CD45RA (c and d). The percentages of RTE Tregs/Tresps (P6, P10), MN Tregs/Tresps (P7, P11), CD31+ memory Tregs/Tresps (P8, P12),
and CD31− memory Tregs/Tresps (P9, P13) were estimated by analyzing the CD4+CD127low+/–FoxP3+ Treg pool (e) and the CD4+CD127+FoxP3−
Tresp pool (f) for its fluorescence intensity of CD31 versus CD45RA. The Ki67 expression of RTE Tregs/Tresps (P14, P18), MN Tregs/Tresps (P15,
P19), CD31+ memory Tregs/Tresps (P16, P20), and CD31− memory Treg/Tresps (P17, P21) were estimated by analyzing the fluorescence intensity
of FoxP3 versus Ki67, respectively (g and h)
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percentages of CD31− memory Tregs were increased, indi-
cating an enhanced differentiation of Tregs in SLE
patients, particularly in young individuals (Fig. 3c). Con-
cerning the differentiation of Tresps, we did not reveal
any significant differences between both study groups
(Fig. 3d). The determination of the different Treg/Tresp
subsets within total CD4+ T cells also showed that there
were no differences concerning the age-dependent dif-
ferentiation of RTE Tregs/Tresps into CD31− memory
Tregs/Tresps between healthy controls and SLE pa-
tients. Age-independent evaluation of Treg/Tresp sub-
sets within the total CD4+ T-cell pool also revealed no
changes regarding Tresp differentiation. However, equal
percentages of RTE Tregs, but significantly increased
percentages of more differentiated Treg subsets (MN
Tregs, CD31+ memory Tregs and CD31− memory
Tregs) were detected within total CD4+ T cells of SLE
patients compared with healthy controls, proposing a
differentiation which rather increases Tregs than Tresps
in SLE patients (Additional file 1: Figure S1).
SLE remission patients show an age-independent
increased differentiation of RTE Tregs via CD31+ memory
Tregs into CD31− memory Tregs, while RTE Tresps
differentiate more strongly via both CD31+ memory
Tresps and MN Tresps
To detect age-related differences in the proliferation of
the different Treg/Tresp subsets, we estimated the per-
centages of Ki67+ cells in healthy volunteers and SLE
patients of different ages. In healthy volunteers, the
proliferation capacity increased significantly in RTE
and MN Tregs/Tresps with age, but did not change in
CD31+ or CD31− memory Tregs/Tresps (Fig. 4a, b). In
SLE patients, this age-dependent increase in the prolif-
eration capacity was preserved in RTE Tregs/Tresps,
and also largely for MN Tregs but not for MN Tresps
(Fig. 4a, b). In addition, we observed an age-
independent significantly decreased proliferation cap-
acity of CD31+ and CD31− memory Tregs, but a signifi-
cantly increased proliferation capacity of all four Tresp
subsets in these patients (Fig. 4a, b). This could be due
Table 1 Clinical characteristics of SLE patients and healthy controls
Healthy
controls
n = 94
SLE
patients
n = 78
SLE patients treated
with glucocorticoids
n = 46
SLE patients not treated
with glucocorticoids
n = 32
SLE patients treated
with MMF or AZA
n = 48
SLE patients not
treated with MMF
or AZA
n = 30
Female sex, n (%) 64
(68%)
65 (83%) 40 (87%) 25 (78%) 38 (79%) 27 (90%)
Age (years) 45 ± 18 45 ± 15 47 ± 16 43 ± 12 43 ± 14 50 ± 16
Time since initial diagnosis (years) – 14 ± 9 14 ± 9 12 ± 9 14 ± 8 14 ± 10
Renal involvement, n (%) – 56 (72%) 38 (87%)* 18 (56%)* 38 (79%) 18 (60%)
Medication
No medication, n (%) 4 (5%) – 4 (13%) – 4 (13%)
Antimalarials, n (%) 62 (79%) 36 (78%) 26 (81%) 40 (83%) 22 (73%)
Mycophenolate mofetil, n (%) 31 (40%) 19 (41%) 12 (38%) 31 (65%) –
Azathioprine, n (%) 17 (22%) 9 (20%) 8 (25%) 17 (35%) –
Glucocorticoids, n (%) 46 (59%) 46 (100%) – 28 (58%) 18 (60%)
Glucocorticoid dose (mg/day) 3.93 ±
1.53
3.93 ± 1.53 – 3.89 ± 1.70 3.99 ± 1.27
Serum leukocytes (n/l) – 6.65 ±
2.36
7.09 ± 2.36 6.02 ± 2.25 6.50 ± 2.55 6.90 ± 2.04
Serum creatinine (mg/dl) – 0.97 ±
0.61
0.94 ± 0.60 1.00 ± 0.64 1.05 ± 0.74 0.84 ± 0.28
CKD-EPI GFR (ml/min/1.73 m2) – 88.6 ±
31.0
88.3 ± 31.2 89.0 ± 31.3 88.0 ± 35.0 89.6 ± 23.9
MDRD GFR (ml/min/1.73 m2) – 88.0 ±
32.8
87.2 ± 31.9 89.2 ± 34.6 87.9 ± 36.7 88.3 ± 26.0
Urine protein/urine creatinine ratio (g/
mol creatinine)
– 44.8 ±
81.6
55.2 ± 98.8 29.7 ± 44.3 62.7 ± 98.8† 16.1 ± 21.5†
A p value < 0.05 was considered significant
The data are presented as their mean and standard deviation unless otherwise indicated
AZA azathioprine, CKD-EPI GFR Chronic Kidney Disease Epidemiology Collaboration-estimated glomerular filtration rate, MDRD GFR Modification of Diet in Renal
Disease study-estimated glomerular filtration rate, MMF mycophenolate mofetil, SLE systemic lupus erythematosus
*, † Significantly differing values between groups (nonparametric H test of Kruskal and Wallis, followed by a Dunn test)
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to the effect of the immunosuppressive therapy redu-
cing the proliferation capacity, especially of those Treg
populations which show significantly increased prolifer-
ation. Consequently, our findings may suggest that, re-
gardless of age, the RTE Tregs differentiate more
strongly via CD31+ memory Tregs into CD31− memory
Tregs in SLE patients compared with healthy controls
(Fig. 4c). In contrast, the age-independent significantly
increased proliferation capacity detected in all Tresp
subsets of SLE patients suggests that RTE Tresps differ-
entiate more strongly via both CD31+ memory Tresps
and MN Tresps into CD31− memory Tresps (Fig. 4d).
Presumably, in SLE patients the proliferation capacity
of the RTE Tresps is severely increased compared with
that of their RTE Tregs, so that the immunosuppressive
therapy regulates the proliferation of the arising Treg
subsets below the normal level; however, is not able to
inhibit the proliferation of the arising Tresp subsets as
effectively.
Compared with healthy controls, SLE patients show
differences concerning their age-dependent
differentiation of Tresps, but not of their Tregs
To further detect differences in the age-dependent dif-
ferentiation between healthy volunteers and SLE pa-
tients, we examined the imminent differentiation of RTE
Tregs/Tresps via MN Tregs/Tresps into CD31− memory
Tregs/Tresps, as well as the differentiation of resting
naive MN Tregs/Tresps into CD31− memory Tregs/
Tresps. For this, we first determined the percentages of
RTE and MN Tregs/Tresps within total naive CD45RA+
Tregs/Tresps, as well as the percentages of MN Tregs/
Tresps within total CD31− Tregs/Tresps with increasing
age. Independent of age, we detected significantly lower
percentages of RTE Tregs (Fig. 5a), but higher percent-
ages of MN Tregs (Fig. 5b) within naive CD45RA+ Tregs
in SLE patients, while the percentages of MN Tregs
within CD31− Tregs were not affected (Fig. 5c). With
age, we found significantly decreasing percentages of
RTE Tregs (Fig. 5a), but increasing percentages of MN
Tregs (Fig. 5b) in the naive CD45RA+ Treg pool, associ-
ated with significantly decreasing percentages of MN
Tregs in the CD31− Treg pool for both study groups
(Fig. 5c). Next, we correlated the percentages of RTE
and MN Tregs within total naive CD45RA+ Tregs and
their Ki67 expression. We found a significant negative
correlation for the percentage of RTE Tregs and their
Ki67 expression in both healthy volunteers and SLE pa-
tients (Fig. 5d). These findings suggest that decreasing
percentages of RTE Tregs within the total naive
CD45RA+ Treg pool are associated with an increased
Ki67 expression of these cells, whereby their differenti-
ation into either MN Tregs or CD31+ memory Tregs
may be strengthened. Neither a significant negative or
positive correlation was detected for MN Tregs within
naive CD45RA+ Tregs and their Ki67 expression in both
CD4+-T-cells
0.0
10.0
20.0
30.0
40.0
50.0
60.0
0 20 40 60 80
Age
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
0 20 40 60 80
Age
p < 0.0001
Tregs Tresps
C
D
4+
-T
-c
el
ls
[%
]
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
0 20 40 60 80
Age
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
40.0
45.0
50.0
0 20 40 60 80
Age
p < 0.01
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
0 20 40 60 80
Age
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
18.0
20.0
0 20 40 60 80
Age
p < 0.01
K
i6
7+
-c
el
ls
 o
fT
re
sp
s 
[%
]
C
D
4+
721
D
C
/
+
wol
-
F
ox
P
3+
-T
re
gs
of
C
D
4+
-T
-c
el
ls
[%
]
K
i6
7+
-c
el
ls
of
T
re
gs
 [%
]
C
D
4+
C
D
12
7+
F
ox
P
3-
-T
re
sp
s
of
C
D
4+
-T
-c
el
ls
[%
]
K
i6
7+
-C
el
ls
 o
fC
D
4+
-T
-c
el
ls
[%
]
A
B C
Fig. 2 The proportion of Ki67+ cells of CD4+ T cells, total CD4+CD127low+/–FoxP3+ regulatory T cells (Tregs) and total CD4+CD127+FoxP3− responder T
cells (Tresps) during the life course in healthy volunteers (n = 94) and SLE patients (n = 78). The percentages of CD4+ T cells within PBMCs (a), and of
total Tregs (b) or total Tresps (c) within the total CD4+ T-helper cell pool, as well as their Ki67 expression, are shown for healthy volunteers
(black diamonds) and SLE patients (red diamonds) during the course of life. The figures present the regression lines concerning the changes
in the percentages of the individual T-cell subsets together with their Ki67 expression with increasing age. Significant age-dependent changes
in healthy volunteers are marked by black p values. Significant age-independent differences between healthy volunteers and SLE patients are
marked by red arrows (red downward and upward arrows) and red p* values
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study groups (Fig. 5e). As RTE Tregs decrease within
total naive Tregs with age, and MN Tregs increase, these
findings suggest that RTE Tregs differentiate increas-
ingly via CD31+ memory Tregs into CD31− memory
Tregs in both healthy volunteers and SLE patients. How-
ever, there was also a significant negative correlation for
the percentage of MN Tregs within total CD31− Tregs
and their Ki67 expression in both study groups (Fig. 5f ),
indicating an age-dependent significantly increased con-
version of resting naive MN Tregs in both healthy vol-
unteers and SLE patients.
In contrast, we did not detect any significant
age-independent differences in the composition of the
naive CD45RA+ Tresp pool with RTE or MN Tresps
between healthy volunteers and SLE patients (Fig. 5g,
h). In addition, the percentage of MN Tresps within
total CD31− Tresps was not affected (Fig. 5i). With age,
we found significantly decreasing percentages of RTE
Tresps but increasing percentages of MN Tresps in
both study groups (Fig. 5g, h), while the percentages of
MN Tresps within total CD31− Tresps increased
slightly but not significantly (Fig. 5i). Both healthy vol-
unteers and SLE patients showed a significant negative
correlation between the percentage of RTE Tresps and
their Ki67 expression indicating that, similar to RTE
Tregs, RTE Tresps show an increased differentiation
with increasing age (Fig. 5j). However, in healthy volun-
teers we found an additional positive correlation be-
tween the percentage of MN Tresps within total naive
CD45RA+ Tresps and their Ki67 expression (Fig. 5k).
These findings suggest that, with age, RTE Tresps of
healthy volunteers differentiate increasingly via MN
Tresps into CD31− memory Tresps. As this correlation
could not be detected for SLE patients (Fig. 5k), it can
be assumed that, with age, the RTE Tresps of these pa-
tients differentiate increasingly via CD31+ memory
Tresps into CD31− memory Tresps. Neither a positive
or negative correlation between the percentage of rest-
ing naive MN Tresps within total CD31− Tresps and
their Ki67 expression could be detected for healthy
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Fig. 3 Changes in the composition of the total regulatory T cell (Treg)/responder T cell (Tresp) pool with age in healthy volunteers (n = 94) and
SLE patients (n = 78). The percentages of recent thymic emigrant (RTE) Tregs/Tresps, mature naive (MN) Tregs/Tresps, CD31+ memory Tregs/Tresps,
and CD31− memory Tregs/Tresps were estimated within the total Treg/Tresp pool in both healthy volunteers (black diamonds) and SLE patients (red
diamonds). The figures present the regression lines concerning the changes in the percentages of the different Treg/Tresp subsets with increasing age.
Significant changes with age are marked by black p values (healthy volunteers) or red p values (SLE patients). Significantly decreased percentages (red
downward arrow) of RTE Tregs, but increased percentages (red upward arrow) of CD31− memory Tregs within total Tregs, independently of
age (marked by red p* values), suggest an enhanced differentiation of RTE Tregs into CD31− memory Tregs in SLE patients compared with
healthy volunteers (a). Age-independent differences in the differentiation of RTE Tresps between healthy volunteers and SLE patients were not
detected (b). The possible differentiation pathways of RTE Tregs/Tresps are illustrated by dashed arrows (c and d). The enhanced differentiation of RTE
Tregs into CD31− memory Tregs is illustrated by a bold arrow (c). Details regarding the enhanced differentiation pathway of RTE Tregs via MN or
CD31+ memory Tregs in SLE patients cannot be determined (d)
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controls (Fig. 5l), indicating that there is no
age-dependent increased conversion of resting naive
MN Tresps into CD31− memory Tresps. However, an
almost significant negative correlation between the per-
centages of resting naive MN Tresps within CD31−
Tresps and their Ki67 expression for SLE patients sug-
gests that there may be a generally increased conver-
sion of these cells into CD31− memory Tresps,
independent of age (Fig. 5l).
Corticosteroids inhibit the proliferation capacity of Tregs
regardless of age
For the treatment of SLE, different immunosuppressive
drugs are used. Figure 6 shows the proliferation cap-
acity of all four Treg/Tresp subsets depending on
whether the patients were treated with corticosteroids
(n = 46) or not (n = 32). These two patient groups dif-
fered clinically only in the fact that renal involvement
was diagnosed significantly more often in patients
treated with glucocorticoids (Table 1). These patients
showed a significantly decreased age-independent
proliferation capacity of their CD31+ and CD31− mem-
ory Treg subsets compared with patients who had not
received these drugs (Fig. 6a). Such findings may sug-
gest that there is an increased age-independent differ-
entiation of RTE Tregs via CD31+ memory Tregs into
CD31− memory Tregs in SLE patients, which ensures
the preservation of the Treg pool, while the prolifera-
tion capacity of the memory Tregs is severely sup-
pressed by corticosteroids. A proliferation-inhibiting
effect of corticosteroids could not be detected for Tresp
cells (Fig. 6b).
Proliferation inhibiting drugs suppress the accelerated
age-dependent differentiation of both RTE-Tregs and RTE-
Tresps via CD31+-memory-Tregs/Tresps
Figure 7 shows the proliferation capacity of all four
Treg/Tresp subsets depending on whether the patients
were treated with either azathioprine (AZA) or myco-
phenolate mofetil (MMF) (n = 48) or not (n = 30).
Clinically, these two patient groups differed regarding
their urine protein/urine creatinine ratio (Table 1).
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Fig. 4 Changes in the Ki67 expression of recent thymic emigrant (RTE), mature naive (MN), CD31+, and CD31− memory regulatory T cells (Tregs)/
responder T cells (Tresps) with age in healthy volunteers (n = 94) and SLE patients (n = 78). The percentages of Ki67+ cells within RTE Tregs/Tresps,
MN Tregs/Tresps, CD31+ memory Tregs/Tresps, and CD31− memory Tregs/Tresps were determined in both healthy volunteers (black diamonds)
and SLE patients (red diamonds) (a and b). The figures present the regression lines concerning the changes of Ki67 expression of the individual
Treg/Tresp subsets with age. Significant changes with age are marked by black p values (healthy volunteers) or red p values (SLE patients). The
age-independent significantly decreased (red downward arrow) percentage of Ki67+ cells within CD31+ memory Tregs and CD31− memory Tregs
(marked by red p* values) suggests an increased differentiation of the RTE Tregs via CD31+ memory Tregs into CD31− memory Tregs in SLE
patients (bold arrows), which is strongly suppressed by the immunosuppressive therapy (a and c). The age-independent significantly increased
(red upward arrow) percentage of Ki67+ cells within all Tresp subsets (marked by red p* values) suggests an increased differentiation of the RTE
Tresps via both MN and CD31+ memory Tresps into CD31− memory Tresps in SLE patients (bold arrows) which is not completely suppressed by
the immunosuppressive therapy (b and d)
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Regardless of age, this medication reduced the prolifer-
ation capacity of RTE and CD31+ memory Tregs sig-
nificantly compared with those who had not received
these drugs (Fig. 7a). Therefore, these results also
emphasize that there is an increased differentiation of
RTE Tregs via CD31+ memory Tregs into CD31−
memory Tregs in SLE patients compared with healthy
controls which is inhibited by the immunosuppressive
therapy. In contrast to the effect of corticosteroids,
there was also an effect of azathioprine or mycopheno-
late mofetil on the proliferative capacity of Tresps. In
SLE patients who did not receive this medication, the
proliferative capacity of RTE Tresps increased signifi-
cantly with age, while this was not the case when aza-
thioprine or mycophenolate mofetil medication was
given to the SLE patients. Also, the proliferation cap-
acity of CD31+ and CD31− memory Tresps did not rise
significantly with age if the SLE patients were not
treated with azathioprine or mycophenolate mofetil,
but it decreased significantly if the SLE patients had
received this medication (Fig. 7b). Astonishingly, simi-
lar results with a clear decrease in the proliferation
capacity of CD31+ and CD31− memory Tregs with age
and a significant difference in the slopes of the
A
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Fig. 5 Changes in the composition of the naive CD45RA+ regulatory T cell (Treg)/responder T cell (Tresp) pool and the CD31− Treg/Tresp pool
during the course of life in healthy volunteers (n = 94) and SLE patients (n = 78). The percentages of recent thymic emigrant (RTE) and mature
naive (MN) Tregs/Tresps within the naive CD45RA+ Treg/Tresp pool, as well as those of MN Tregs/Tresps within the total CD31− Treg/Tresp pool,
were estimated in healthy volunteers (black diamonds) and SLE patients (red diamonds). The figures present the regression lines concerning the
changes of the Treg/Tresp subsets with age (a–c and g–i) or with their Ki67-expression (d–f and j–l). Significant changes with age are marked by
black p values (healthy volunteers) or red p values (SLE patients). In SLE patients, age-independent significantly decreased (red downward arrow)
percentages of RTE Tregs within the naive CD45RA+ Treg pool (a) but increased (red upward arrow) percentages of MNs within the naive CD45RA+
Treg pool (b) (marked by red p* values) were detected, but not for RTE Tresps or for MN Tresps within the total CD45RA+ Tresp pool (g and h). A
significant negative correlation between the percentage of RTE Tregs/Tresps and their Ki67 expression was found for both healthy volunteers and SLE
patients (d and j). A significant correlation between the percentage of MN Tregs within total naive CD45RA+ Tregs and their Ki67 expression was not
found for healthy volunteers or for SLE patients (e). A significant positive correlation was found between the percentage of MN Tresps within total
naive CD45RA+ Tresps and their Ki67 expression which could not be assessed for SLE patients (k). The percentage of resting naive MN Tregs within
total CD31− Tregs decreased significantly with age (c), while that of resting naive MN Tresps increased slightly, but not significantly, within total CD31−
Tresps (i). A significant negative correlation between the percentage of resting naive MN Tregs within total CD31− Tregs and their Ki67 expression was
found for both study groups (f). In contrast, the percentage of MN Tresps within CD31− Tresps did not correlate with their Ki67 expression in healthy
controls but showed a nearly significant negative correlation for SLE patients (l)
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Fig. 6 Changes of the Ki67 expression of recent thymic emigrant (RTE), mature naive (MN), CD31+, and CD31− memory regulatory T cells (Tregs)/
responder T cells (Tresps) with age in healthy volunteers (n = 94) and SLE patients, divided into patients treated with glucocorticoids (n = 46) or
not (n = 32). The percentages of Ki67+ cells within RTE, MN, CD31+, and CD31− memory Tregs/Tresp was estimated in healthy volunteers (black
diamonds) and in SLE patients who were treated with glucocorticoids (red diamonds) or not (green diamonds). An age-independent significantly
decreased (red downward arrow) percentage of Ki67+ cells was detected in CD31+ and CD31− memory Tregs (marked by red p* values) in
glucocorticoid-treated versus untreated SLE patients (a). A similarly reduced expression of Ki67+ cells in CD31+ and CD31− memory Tresps of
glucocorticoid-treated SLE patients was not detected (b)
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Fig. 7 Changes of the Ki67 expression of recent thymic emigrant (RTE), mature naive (MN), CD31+, and CD31− memory regulatory T cells (Tregs)/
responder T cells (Tresps) with age in healthy volunteers (n = 94) and SLE patients who were treated with MMF or AZA (n = 48) or not (n = 30).
The percentages of Ki67+ cells within RTE, MN, CD31+, and CD31− memory Tregs/Tresp was estimated in healthy volunteers (black diamonds) and
in SLE patients who were treated with MMF or AZA (blue diamonds) or not (green diamonds). Significant changes with age are marked by blue p
values (treated with AZA or MMF) or green p values (no AZA or MMF medication). An age-independent significantly decreased (blue downward
arrow) percentage of Ki67+ cells was detected in RTE Tregs and CD31+ memory Tregs (marked by blue p* values) of AZA- or MMF-treated versus
untreated SLE patients (a). Moreover, in SLE patients who did not receive AZA or MMF the proliferative capacity of RTE Tresps increased significantly
with age, while this was not the case when AZA or MMF medication was given to the SLE patients. The proliferation capacity of CD31+ and CD31−
memory Tresps did not rise significantly with age if the SLE patients were not treated with AZA or MMF, but it decreased significantly if the SLE
patients had been treated with AZA or MMF (b). Similar results, with a clear decrease in the proliferation capacity of CD31+ and CD31− memory Tregs
with age and a significant difference in the slopes of the regression lines between treated and untreated SLE patients, were also observed for Tregs (a)
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regression lines (p < 0.01) between treated and un-
treated SLE patients were also observed (Fig. 7a).
These findings also suggest that there is an age-
dependent increased differentiation of both RTE Tregs
and RTE Tresps via CD31+ memory Tregs/Tresps into
CD31− memory Tregs/Tresps in SLE patients which is
strongly suppressed by azathioprine or mycophenolate
mofetil medication. This medication seems to be of
particular importance since these substances seem to
selectively inhibit the accelerated age-dependent differ-
entiation of RTE Tresps via CD31+ memory Tresps
into CD31− memory Tresps, and at the same time in-
hibit the differentiation of RTE Tregs via CD31+ mem-
ory Tregs into CD31− memory Tregs. It is striking that
this medication reduces the age-dependent prolifera-
tion capacity of the memory Tregs from normal to
reduced levels but that of memory Tresps from in-
creased to normal levels.
SLE patients show an impairment of both Treg and Tresp
functionality
To examine whether there were age-related differ-
ences in the suppressive activity of separated naive
CD45RA+ and CD45RA− memory Tregs, the total
CD4+CD127low+/–CD25+ Treg pool of 40 healthy vol-
unteers (mean age 41 ± 17 years) and 37 SLE patients
(mean age 49 ± 13 years) was isolated by magnetic-
activated cell sorting (MACS) and sorted into both
Treg subsets (Fig. 8a). Subsequently, the isolated
CD45RA+ naive Tregs and CD45RA− memory Tregs
were analyzed separately for their suppressive capacity.
We found that the suppressive activity of both naive
CD45RA+ and CD45RA− memory Tregs of healthy con-
trols increased significantly with age, while this could not
be maintained in SLE patients (Fig. 8b, c). Moreover, re-
gardless of age, the functionality of both Treg subsets was
significantly diminished in SLE patients compared with
healthy volunteers (Fig. 8b, c).
To further clarify whether the Treg function of SLE
patients is diminished or Tresp function is enhanced,
we examined the suppressive activity of CD45RA+ naive
Tregs and CD45RA− memory Tregs purified from 14
middle-aged SLE patients (mean age 49 ± 11 years) with
both autologous Tresps and nonautologous Tresps
purified from age-matched healthy volunteers (mean
age 43 ± 14 years). Furthermore, the suppressive activity
of both Treg subsets separated from healthy volunteers
was tested with both autologous Tresps and nonautolo-
gous Tresps purified from age-matched SLE patients.
Figure 8d and e show that the maximum suppressive
activity of both naive CD45RA+ and CD45RA− memory
Tregs of SLE patients was significantly lower than that
of healthy volunteers when tested with autologous
Tresps. When tested with nonautologous Tresps of
healthy volunteers, their suppressive activity was in-
creased; however, statistical significance was not
achieved. Nevertheless, the Tregs of healthy volunteers
were able to suppress the Tresps of SLE patients as well
as their own Tresps. In addition, the suppressive activ-
ity of both naive CD45RA+ and CD45RA− memory
Tregs of SLE patients was significantly lower when
tested on nonautologous Tresps of healthy volunteers
compared with the suppressive activity of Tregs of
healthy volunteers tested on their own Tresps. In sum-
mary, our findings suggest that both Tregs and Tresps
are functionally disturbed in SLE patients. Thereby, it
seems that the diminished sensitivity of their Tresps for
the inhibition by their Tregs, which obviously aggra-
vates with age in these patients, is relatively well con-
trolled by the currently used immunosuppressive
therapy. However, this therapy may also have the effect
of reducing Treg functionality.
Discussion
It has been known for many years that an increased
CD4+ T-cell stimulation in SLE patients leads to the ac-
cumulation of terminal differentiated effector memory T
cells with decreased proliferative capacity and increased
apoptosis sensitivity [22–25]. Consequently, a reduction
in circulating CD4+ T cells was found in these patients
[26]. However, until now the particular role of immuno-
suppressive CD4+ Tregs or CD4+ effector Tresps in the
pathogenesis of SLE remains elusive. An imbalance in
the ratio of Tregs to Tresps is thought to be the most
important cause of the disturbed T-cell signaling in SLE
patients. The mechanisms that trigger this imbalance are
currently being investigated more intensively.
In this study, we examined the differentiation of RTE
Tregs/Tresps into CD31− memory Tregs/Tresps and
verified whether changes in the differentiation pathway
via MN Tregs/Tresp or CD31+ memory Tregs/Tresps
had an effect on the balance between Tregs and Tresps
which may affect the functionality of the Treg pool. We
found an increased differentiation of RTE Tregs/Tresps
into CD31− memory Tregs/Tresps with age in both
healthy volunteers and SLE patients. However, regardless
of age, SLE patients revealed a greater differentiation of
the Treg pool, but did not show differences in the Tresp
pool. The Ki67 staining of the different Treg/Tresp cell
subsets revealed a significant age-independent reduction
in CD31+ and CD31− memory Treg proliferation, suggest-
ing a predominant differentiation via CD31+ memory
Tregs in SLE patients, which most probably is strongly re-
strained by the immunosuppressive drugs, even below the
normal level of healthy volunteers. In contrast, all Tresp
subsets showed significantly increased proliferation suggest-
ing an age-independent increased RTE Tresp cell differenti-
ation via both pathways in spite of the immunosuppressive
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therapy. Our experiences with pregnant women and
dialysis and transplant patients suggest that the favored
differentiation pathway of RTE Tregs/Tresps via CD31+
memory Tregs/Tresps or MN Tregs/Tresps may in-
crease or reduce the apoptosis sensitivity of the arising
CD31− memory Tregs/Tresps [14, 17, 27]. Conse-
quently, our data assume that the size of the Treg pool
should be largely maintained in SLE patients, while that
of the Tresp pool should be diminished due to reduced
production and increased consumption of resting naive MN
Tresps. Nevertheless, it is expected that the functionality of
the Treg pool will be weakened as the proliferation capacity
of memory Tregs was found to be reduced below the level
of healthy controls.
Figure 9 summarizes the different age-dependent and
age-independent differentiation pathways of RTE
Tregs/Tresps in both healthy controls and SLE patients.
It can be assumed that in both the total Treg and the
total Tresp pool a population of resting naive MN
Tregs/Tresps exists during the course of life [28]. For
healthy controls, it appears that RTE Tregs differentiate
increasingly via CD31+ memory Tregs into CD31−
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Fig. 8 Suppressive activity of naive CD45RA+ regulatory T cells (Tregs) and CD45RA− memory Tregs obtained from healthy volunteers (n = 40)
and systemic lupus erythematosus (SLE) patients (n = 37). Total CD4+CD127low+/–CD25+ Tregs were isolated by magnetic-activated cell sorting
(MACS), stained with anti-CD45RA and CD45RO monoclonal antibodies and sorted into CD45RA− memory Tregs (P1) and naive CD45RA+ Tregs
(P2) (a). The suppressive activity of both Treg subsets was estimated with autologous Tresp for healthy volunteers (black diamonds) and SLE
patients (red diamonds). The figure shows the individual and median values of the maximum suppressive activity (Treg/Tresp = 1/2) and of the
ratio of Treg to Tresp up to which the purified CD45RA+ and CD45RA− Treg subsets could be diluted to achieve a minimum suppressive activity
of at least 15% (b and c). In healthy volunteers, the suppressive activity of both Treg subsets increased significantly with age. However, this could
not be sustained for SLE patients (b and c). Furthermore, the suppressive activity of both Treg subsets obtained from healthy volunteers (n = 14)
and SLE patients (n = 14) was tested with nonautologous Tresps of age-matched SLE patients and nonautologous Tresps of age-matched healthy
volunteers. The suppressive activity of both Treg subsets from SLE patients was significantly reduced when tested with both autologous and
nonautologous Tresps of healthy volunteers (d and e)
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memory Tregs. However, there is also an increased
conversion of resting naive MN Tregs into CD31−
memory Tregs with age (Fig. 9a). On the other hand,
an increased differentiation of RTE Tresps via MN
Tresps into CD31− memory Tresps was observed in
healthy controls, whereby resting naive MN Tresps
were rather enriched within the total CD31− Tresp pool
instead of being converted into CD31− memory Tresps
(Fig. 9b). For SLE patients, a similar age-dependent dif-
ferentiation could be revealed for RTE Tregs (Fig. 9a).
However, in contrast to healthy controls, RTE Tresps of
SLE patients differentiated increasingly via CD31+
memory Tresps into CD31− memory Tresps (Fig. 9b).
This altered differentiation of RTE Tresps suggests that
highly apoptosis-resistant Tresps may arise, particularly
in old-aged SLE patients, which reduces the autologous
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Fig. 9 Age-dependent and age-independent differentiation of regulatory T cells (Tregs)/responder T cells (Tresps) in healthy volunteers and SLE
patients. The figure summarizes our findings concerning the age-dependent (a and b) and age-independent (c and d) differentiation of recent
thymic emigrant (RTE) Tregs (a and c) or RTE Tresps (b and d) via mature naive (MN) Tregs/Tresps or CD31+ memory Tregs/Tresps into CD31−
memory Tregs/Tresps for healthy controls (black arrows) and SLE patients (red arrows). An age-dependent increased differentiation of RTE Tregs
via CD31+ memory Tregs into CD31− memory Tregs, as well as an age-dependent increased conversion of resting naive MN Tregs into CD31−
memory Tregs, was found for both healthy controls and SLE patients (a, illustrated by red and black bold arrows). In contrast, with increasing age,
an opposite differentiation was found for RTE Tresps, which differentiated increasingly via MN Tresp into CD31− memory Tresps in healthy
controls, while those of SLE patients differentiated via CD31+ memory Tresps into CD31− memory Tresps (b, illustrated by black and red bold
arrows). An age-dependent increased differentiation of resting naive MN Tresps into CD31− memory Tresps was not found for healthy controls or
for SLE patients (b). Regarding the age-independent differentiation, our findings show an increased differentiation of RTE Tregs/Tresps via CD31+
memory Tregs/Tresps into CD31− memory Tregs/Tresps in SLE patients compared with healthy controls (c and d, illustrated by red bold arrows).
Additionally, we found an age-independent increased conversion of resting naive MN Tresps into CD31− memory Tresps in SLE patients compared
with healthy controls (d, illustrated by a red bold arrow). These mechanisms may lead to an imbalance between Tregs and Tresps in favor of Tregs (e),
especially when the pool of these resting naive MN Tresps is no longer filled up
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Treg function in these patients. These results are in line
with clinical observations that old age-onset SLE is not
benign and more disease activity and damage are
present in these patients [29]. Such findings are con-
firmed by our data showing a significant increase of the
Treg function with age in healthy volunteers, which
cannot be maintained in SLE patients. In addition, our
investigations testing the Treg function of SLE patients
on both autologous and nonautologous Tresps also
show that the suppressive activity of SLE Tregs is in-
deed reduced when tested with autologous Tresps, but
it is better, though not significantly so, when tested
with nonautologous Tresps of healthy controls. These
findings suggest that the sensitivity of Tresps to the
suppressive function of Tregs may be reduced in SLE
patients. Similar results were published by Venigalla
et al., who also showed impaired Tresp sensitivity to
the suppressive function of both autologous and nonau-
tologous Tregs isolated from patients with active SLE,
where the functionality of Tregs was fully preserved
[30]. These data are in line with results using a mouse
lupus model, in which similar crossover experiments re-
vealed an impaired Tresp cell sensitivity in MRL/Mp mice
[31]. In contrast, our data reveal that Tregs obtained from
SLE patients showed limited functionality when tested
with both autologous Tresps and allogeneic Tresps from
healthy volunteers, indicating a generally impaired Treg
functionality in SLE remission patients.
Beside these differences concerning the age-dependent
differentiation of RTE Tregs/Tresps between healthy
controls and SLE patients, our data also reveal that there
may be a general age-independent increased differenti-
ation of RTE Tregs/Tresps via CD31+ memory Tregs/
Tresps into CD31− memory Tregs/Tresps in SLE pa-
tients compared with healthy controls (Fig. 9c, d). How-
ever, in contrast to healthy controls who rather enrich
resting naive MN Tresps, there seems to be an increased
age-independent conversion and consumption of MN
Tresps in SLE patients (Fig. 9d). This mechanism may
affect the balance between Tregs and Tresps substan-
tially (Fig. 9e), especially when the pool of these resting
naive MN Tresps is no longer filled up. Presumably, this
phenomenon may be strongly pronounced in patients
with active disease.
It should be considered that, in our study, Tregs and
Tresps were exclusively isolated from patients in remis-
sion but not from patients with active SLE. Therefore,
exaggerated Treg/Tresp cell activation may have been
largely restrained by extensive immunosuppression
therapy. Therefore, it is striking that azathioprine or
mycophenolate mofetil medication specifically and sub-
stantially reduced the accelerated age-dependent in-
crease of RTE Tresps differentiation via CD31+
memory Tresps into CD31− memory Tresps. A similar
effect of this medication was also found for the acceler-
ated age-dependent differentiation of RTE Tregs. How-
ever, this reduced the proliferation capacity of the
arising memory Tregs far below the normal level of
healthy controls, while that of the resulting Tresps was
reduced from increased to normal levels. This may be
caused by the fact that the initial degree of activation of
the RTE Tresps is strongly increased in SLE patients
compared with that of healthy volunteers. While the ef-
fect of these substances on the Tresps is desired, their
effect on Tregs is adverse. Corticosteroid therapy did
not have any effect on Tresp differentiation or prolifer-
ation. However, it strongly reduced the proliferative
capacity of the memory Tregs. A drug-induced reduc-
tion in Treg functionality due to diminished prolifera-
tion capacity of the memory Tregs could therefore be
observed in SLE remission patients and be the cause
for ongoing discussions regarding the effectiveness of
corticoid treatment [32], although it was shown to
cause Treg cell expansion [33, 34].
Current discrepancies concerning the number and
function of Tregs in SLE patients will probably mainly
arise from the fact that different collectives regarding
the activation status of the patients were examined. It
seems quite clear that decreased Treg cell counts and
reduced functionality were mainly found in patients
with high clinical disease activity [35, 36]. It still re-
mains unclear whether or which specific Treg subsets
are affected and to what extent the differentiation or
stability of individual Treg subsets is impaired. More
selective agents that have less negative influence on
Treg differentiation would be desirable, and rapamycin
is increasingly coming into focus. While this substance
does not yet play a role in the treatment of SLE pa-
tients, there is increasing clinical evidence of potentially
good efficacy in SLE patients [37]. Its mechanistic tar-
get is mTOR, an evolutionally conserved kinase con-
sisting of two interacting complexes (mTORC1 and
mTORC2) that regulate T-cell lineage specification and
macrophage differentiation [38]. It was shown that
mTOR is highly activated in Tregs of SLE patients and
that mTORC1 and mTORC2 were stimulated by IL-21,
by which the differentiation and function of the Treg
cells was abrogated. Rapamycin treatment restored
Treg function [39], indicating that mTOR signaling in
Tregs constitutes a potential checkpoint in lupus
pathogenesis. Moreover, mTOR signaling also controls
the differentiation of multiple effector T cells, including
Th1, Th2, Th17, and particularly that of follicular
T-helper (Tfh) cells [40, 41]. Such Tfh cells are known
to provide optimal B cell-mediated humoral immunity
and were shown to be involved in the pathogenesis of
SLE, whereby the ratio of circulating Tfh to follicular T
regulatory (Tfr) cells is correlated with disease activity
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in SLE [42, 43]. Another interesting therapeutic effect
of rapamycin is its ability to reverse the senescent
phenotype of mesenchymal stem cells from MRL/lpr
mice and SLE patients through inhibition of the mTOR
signaling pathway [44], suggesting that cellular senes-
cence of cells constituting the microenvironment of
hematopoietic stem cells may play an important role in
the pathogenesis of SLE. Further studies confirm that
such immunosuppressive mesenchymal stem cells show
characteristic signs of senescence [45–47] and therefore
suggest that allogeneic rather than autologous mesen-
chymal stem cell transplantation may be promising in
the treatment of drug-resistant SLE [48].
Conclusions
In summary, our data reveal that there is a potential ef-
fect of the currently used therapeutics especially on the
age-dependent accelerated T-cell differentiation in SLE
patients. Therefore, it seems likely that the disruption
of immunosuppression in active SLE causes severe dif-
ferentiation, senescence, and depletion of T cells,
whereby the favorable ratio of Tregs/Tresps in SLE re-
mission patients may be changed in favor of Tresps.
The identification of the special Treg/Tresp subsets in-
volved in these mechanisms may be helpful for further
elucidation of the pathogenesis of SLE and for develop-
ment of effective therapeutic strategies in the treatment
of SLE.
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